P2X7受体在结肠癌进展中的作用

doi:10.3760/cma.j.cn371439-20200903-00050

国际肿瘤学杂志 ›› 2021, Vol. 48 ›› Issue (4): 250-253.doi: 10.3760/cma.j.cn371439-20200903-00050

P2X7受体在结肠癌进展中的作用

李倩倩, 朱晓娣, 赵荣兰, 彭效祥()

潍坊医学院医学检验学院纳米医学技术研究所潍坊医学院临床检验诊断学山东省“十二五”高校重点实验室 261053

收稿日期:2020-09-03 修回日期:2020-12-10 出版日期:2021-04-08 发布日期:2021-06-18
通讯作者: 彭效祥 E-mail:pxx74@sina.com
基金资助:
国家自然科学基金(81770915);国家自然科学基金(81301737)

Role of P2X7 receptor in colon cancer progression

Li Qianqian, Zhu Xiaodi, Zhao Ronglan, Peng Xiaoxiang()

Institute of Nanomedical Technology, School of Laboratory Medicine, Weifang Medical University & Key Laboratory of Clinical Laboratory Diagnostics, 12th 5-Year Project of Shandong Province, Weifang Medical University, Weifang 261053, China

Received:2020-09-03 Revised:2020-12-10 Online:2021-04-08 Published:2021-06-18
Contact: Peng Xiaoxiang E-mail:pxx74@sina.com
Supported by:
National Natural Science Foundation of China(81770915);National Natural Science Foundation of China(81301737)

摘要/Abstract

摘要：

P2X7受体是以三磷酸腺苷(ATP)为配体的离子通道型受体,在多种免疫细胞和组织中广泛表达,其激活后可参与多种生理和病理过程。P2X7受体在结肠癌中异常表达,并在结肠癌的进展中发挥抑癌和促癌双重作用。P2X7受体被细胞外的ATP激活后,可通过多种机制有效抑制结肠癌细胞的增殖,并诱导细胞凋亡。另外,P2X7受体还能促进结肠癌的生长、侵袭和转移。了解P2X7受体的激活及其效应机制对于结肠癌的治疗具有重要意义。

关键词: 受体, 嘌呤能P2X7, 结肠肿瘤, 三磷酸腺苷

Abstract:

P2X7 receptor is an ion channel receptor with adenosine triphosphate (ATP) as its ligand, which is widely expressed in various immune cells and tissues. Activated P2X7 receptor is involved in a variety of physiological and pathological processes. P2X7 receptor is abnormally expressed in colon cancer, and plays a duel role of cancer-promoting and cancer-suppressing in colon cancer progression. When P2X7 receptor is activated by extracellular ATP, it can effectively inhibit proliferation and induce apoptosis of colon cancer cells through various mechanisms. In addition, P2X7 receptor can also promote the growth, invasion and metastasis of colon cancer. Understanding the activation of P2X7 receptor and its effect mechanism is of great significance for the treatment of colon cancer.

Key words: Receptors, purinergic P2X7, Colonic neoplasms, Adenosine triphosphate

李倩倩, 朱晓娣, 赵荣兰, 彭效祥. P2X7受体在结肠癌进展中的作用[J]. 国际肿瘤学杂志, 2021, 48(4): 250-253.

Li Qianqian, Zhu Xiaodi, Zhao Ronglan, Peng Xiaoxiang. Role of P2X7 receptor in colon cancer progression[J]. Journal of International Oncology, 2021, 48(4): 250-253.

参考文献 28

[1]	Lv Y, Yang X, Wang L. Effect of lncRNA THOR on proliferation and migration of colon cancer cells[J]. Oncol Lett, 2019, 18(3):2518-2522. DOI: 10.3892/ol.2019.10585.
[2]	Di Virgilio F, Pelegrín P. Editorial overview: purinergic P2X receptors in innate immunity and inflammation[J]. Curr Opin Pharmacol, 2019, 47:141-144. DOI: 10.1016/j.coph.2019.05.003. doi: 10.1016/j.coph.2019.05.003
[3]	Zhang WJ, Hu CG, Zhu ZM, et al. Effect of P2X7 receptor on tumorigenesis and its pharmacological properties[J]. Biomed Pharmacother, 2020, 125:109844. DOI: 10.1016/j.biopha.2020.109844. doi: 10.1016/j.biopha.2020.109844
[4]	Roger S, Jelassi B, Couillin I, et al. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives[J]. Biochim Biophys Acta, 2015, 1848(10 Pt B):2584-2602. DOI: 10.1016/j.bbamem.2014.10.029. doi: 10.1016/j.bbamem.2014.10.029
[5]	Cao F, Hu LQ, Yao SR, et al. P2X7 receptor: a potential therapeutic target for autoimmune diseases[J]. Autoimmun Rev, 2019, 18(8):767-777. DOI: 10.1016/j.autrev.2019.06.009. doi: 10.1016/j.autrev.2019.06.009
[6]	Ribeiro DE, Roncalho AL, Glaser T, et al. P2X7 receptor signaling in stress and depression[J]. Int J Mol Sci, 2019, 20(11): 2778. DOI: 10.3390/ijms20112778. doi: 10.3390/ijms20112778
[7]	Di Virgilio F, Adinolfi E. Extracellular purines, purinergic receptors and tumor growth[J]. Oncogene, 2017, 36(3):293-303. DOI: 10.1038/onc.2016.206. doi: 10.1038/onc.2016.206 pmid: 27321181
[8]	Furini F, Giuliani AL, Parlati ME, et al. P2X7 receptor expression in patients with serositis related to systemic lupus erythematosus[J]. Front Pharmacol, 2019, 10:435. DOI: 10.3389/fphar.2019.00435. doi: 10.3389/fphar.2019.00435
[9]	Amoroso F, Salaro E, Falzoni S, et al. P2X7 targeting inhibits growth of human mesothelioma[J]. Oncotarget, 2016, 7(31):49664-49676. DOI: 10.18632/oncotarget.10430. doi: 10.18632/oncotarget.v7i31
[10]	Choi JH, Ji YG, Ko JJ, et al. Activating P2X7 receptors increases proliferation of human pancreatic cancer cells via ERK1/2 and JNK[J]. Pancreas, 2018, 47(5):643-651. DOI: 10.1097/MPA.0000000000001055. doi: 10.1097/MPA.0000000000001055 pmid: 29683976
[11]	Xia J, Yu X, Tang L, et al. P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway[J]. Oncol Rep, 2015, 34(1):103-110. DOI: 10.3892/or.2015.3979. doi: 10.3892/or.2015.3979
[12]	Hofman P, Cherfils-Vicini J, Bazin M, et al. Genetic and pharmacological inactivation of the purinergic P2RX7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitis-associated cancer[J]. Cancer Res, 2015, 75(5):835-845. DOI: 10.1158/0008-5472.CAN-14-1778. doi: 10.1158/0008-5472.CAN-14-1778
[13]	陆嫄, 顾沐恩, 丁邦友, 等. 艾灸对结肠炎相关性结肠癌大鼠P2X7受体、Wnt/β-catenin信号通路影响的研究[J]. 上海针灸杂志, 2020, 39(6):758-765. DOI: 10.13460/j.issn.1005-0957.2020.13.1042.
[14]	Wang J, Cheng M, Law IKM, et al. Cathelicidin suppresses colon cancer metastasis via a P2RX7-dependent mechanism[J]. Mol Ther Oncolytics, 2019, 12:195-203. DOI: 10.1016/j.omto.2019.01.004. doi: 10.1016/j.omto.2019.01.004
[15]	Adinolfi E, Capece M, Franceschini A, et al. Accelerated tumor progression in mice lacking the ATP receptor P2X7[J]. Cancer Res, 2015, 75(4):635-644. DOI: 10.1158/0008-5472.CAN-14-1259. doi: 10.1158/0008-5472.CAN-14-1259
[16]	Di Virgilio F, Sarti AC, Falzoni S, et al. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment[J]. Nat Rev Cancer, 2018, 18(10):601-618. DOI: 10.1038/s41568-018-0037-0. doi: 10.1038/s41568-018-0037-0
[17]	He Y, Taylor N, Fourgeaud L, et al. The role of microglial P2X7: modulation of cell death and cytokine release[J]. J Neuroinflammation, 2017, 14(1):135. DOI: 10.1186/s12974-017-0904-8. doi: 10.1186/s12974-017-0904-8
[18]	Bian S, Sun X, Bai A, et al. P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death[J]. PLoS One, 2013, 8(4): e60184. DOI: 10.1186/s12974-017-0904-8. doi: 10.1371/journal.pone.0060184
[19]	Coutinho-Silva R, Stahl L, Cheung KK, et al. P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation[J]. Am J Physiol Gastrointest Liver Physiol, 2005, 288(5): G1024-G1035. DOI: 10.1152/ajpgi.00211.2004. doi: 10.1152/ajpgi.00211.2004
[20]	Souza CO, Santoro GF, Figliuolo VR, et al. Extracellular ATP induces cell death in human intestinal epithelial cells[J]. Biochim Biophys Acta, 2012, 1820(12):1867-1878. DOI: 10.1016/j.bbagen.2012.08.013.
[21]	de Andrade Mello P, Bian S, Savio LEB, et al. Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death[J]. Oncotarget, 2017, 8(40):67254-67268. DOI: 10.18632/oncotarget.18595. doi: 10.18632/oncotarget.v8i40
[22]	Adinolfi E, Raffaghello L, Giuliani AL, et al. Expression of P2X7 receptor increases in vivo tumor growth[J]. Cancer Res, 2012, 72(12):2957-2969. DOI: 10.1158/0008-5472.CAN-11-1947. doi: 10.1158/0008-5472.CAN-11-1947
[23]	Janakiram NB, Mohammed A, Bryant T, et al. Adoptive transfer of regulatory T cells promotes intestinal tumorigenesis and is associated with decreased NK cells and IL-22 binding protein[J]. Mol Carcinog, 2015, 54(10):986-998. DOI: 10.1002/mc.22168. doi: 10.1002/mc.22168
[24]	方伟岗, 田新霞. 肿瘤微环境中一种新型促侵袭因子的发现——细胞外ATP功能及机制的研究进展[J]. 北京大学学报(医学版), 2017, 49(2):188-195. DOI: 10.3969/j.issn.1671-167X.2017.02.002.
[25]	Zhang Y, Ding J, Wang L. The role of P2X7 receptor in prognosis and metastasis of colorectal cancer[J]. Adv Med Sci, 2019, 64(2):388-394. DOI: 10.1016/j.advms.2019.05.002. doi: 10.1016/j.advms.2019.05.002
[26]	Qian F, Xiao J, Hu B, et al. High expression of P2X7R is an in-dependent postoperative indicator of poor prognosis in colorectal cancer[J]. Hum Pathol, 2017, 64:61-68. DOI: 10.1016/j.humpath.2017.03.019. doi: 10.1016/j.humpath.2017.03.019
[27]	Kaltschmidt B, Greiner JFW, Kadhim HM, et al. Subunit-specific role of NF-κB in cancer[J]. Biomedicines, 2018, 6(2):44. DOI: 10.3390/biomedicines6020044. doi: 10.3390/biomedicines6020044
[28]	Xia Y, Shen S, Verma IM. NF-κB, an active player in human can-cers[J]. Cancer Immunol Res, 2014, 2(9):823-830. DOI: 10.1158/2326-6066.CIR-14-0112. doi: 10.1158/2326-6066.CIR-14-0112

P2X7受体在结肠癌进展中的作用

Role of P2X7 receptor in colon cancer progression

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 28

相关文章 15

编辑推荐

Metrics

本文评价

[1]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[2]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[3]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[4]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[5]	张丽, 向卓, 王强, 毕经旺. CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381.
[6]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[7]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[8]	李佳璇, 封颖璐. 糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.
[9]	宁婷婷, 胡钦勇, 李倩, 杨鹏程. 奥希替尼与埃克替尼一线治疗EGFR阳性转移性NSCLC临床疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 65-70.
[10]	张碧霞, 丁江华. EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101.
[11]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.
[12]	许婷婷, 胡超苏, 李宝生. 抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(1): 1-11.
[13]	徐航程, 吴云, 王佳玉. HER2低表达乳腺癌研究进展[J]. 国际肿瘤学杂志, 2022, 49(9): 513-516.
[14]	褚雪镭, 毛昀, 薛鹏, 李林潞, 陈美池, 袁淳晟, 秦晓艳, 朱世杰. 化疗剂量强度对晚期结肠癌患者近期疗效的影响：基于真实世界数据研究[J]. 国际肿瘤学杂志, 2022, 49(7): 408-415.
[15]	徐忠玲, 王珏, 郑广, 何欣. 卡瑞利珠单抗联合阿帕替尼治疗十二指肠癌1例[J]. 国际肿瘤学杂志, 2022, 49(7): 447-448.